Fruquintinib Plus S-1 and Raltitrexed (RSF) for MCRC

Summary

Based on the FRECO-2 study, Fruquintinib has become one of the standard third-line treatments for advanced colorectal cancer; however, its objective response rate (ORR) remains low. Our previous studies have shown that the combination of raltitrexed and S-1 -/+ bevacizumab is effective and provides a significant survival benefit in patients with metastatic colorectal cancer (mCRC) who are refractory to standard treatments. This study aims to evaluate the efficacy and safety of combining Fruquintinib with S-1 and raltitrexed in these patients.

Timeline

Start

2023-02-20

Primary completion

2025-08-18

Completion

2026-04-30

Publications

• Leng W, Wen Z, Wang H, Cao P, Liu J, Luo D, Qiu M. Raltitrexed, S-1 and fruquintinib (RSF) in the treatment of refractory metastatic colorectal cancer: study protocol for a multicenter, prospective, single-arm, phase II trial. BMC Cancer. 2025 Feb 28;25(1):376. doi: 10.1186/s12885-025-13654-7.

Drugs

Indications

No indication recorded.